Evidence map›Paper›PMID 36409128›Full record

ArticleAntimicrobial agents and chemotherapy2022

Spirofused Tetrahydroisoquinoline-Oxindole Hybrids (Spiroquindolones) as Potential Multitarget Antimalarial Agents: Preliminary Hit Optimization and Efficacy Evaluation in Mice.

Noella M Efange, Maloba M M Lobe, Lauve R T Yamthe, Jeannette N M Pekam, Protus A Tarkang, Lawrence Ayong, Simon M N Efange

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Noella M EfangeDepartment of Biochemistry & Molecular Biology, University of Buea, Buea, Southwest Region, Cameroon.
Maloba M M LobeDepartment of Chemistry, University of Buea, Buea, Southwest Region, Cameroon.
Lauve R T YamtheInstitut de Recherches Medicales et d'Etudes des Plantes Medicinales (IMPM), Yaoundé, Cameroon.
Jeannette N M PekamMalaria Research Unit, Centre Pasteur du Cameroungrid.418179.2, Yaoundé, Cameroon.
Protus A TarkangInstitut de Recherches Medicales et d'Etudes des Plantes Medicinales (IMPM), Yaoundé, Cameroon.
Lawrence AyongMalaria Research Unit, Centre Pasteur du Cameroungrid.418179.2, Yaoundé, Cameroon.ORCID 0000-0001-7717-4832
Simon M N EfangeDepartment of Biochemistry & Molecular Biology, University of Buea, Buea, Southwest Region, Cameroon.
University of Buea · CMCentre Pasteur du Cameroun · CMInstitut de Recherches Médicales et d’Etudes des Plantes Médicinales · CM

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previous studies suggest that 3',5'-dihydro-2'H-spiro[indoline-3,1'-isoquinolin]-2-ones (DSIIQs [spiroquindolones]) are multitarget antiplasmodial agents that combine the actions of spiroindolone and naphthylisoquinoline antimalarial agents. In this study, 12 analogues of compound (±)-5 (moxiquindole), the prototypical spiroquindolone, were synthesized and tested for antiplasmodial activity. Compound (±)-11 (a mixture of compounds 11a and 11b), the most potent analogue, displayed low-nanomolar activity against P. falciparum chloroquine-sensitive 3D7 strain (50% inhibitory concentration [IC

Indexed as

AntimalarialsMalaria, FalciparumTetrahydroisoquinolinesAnimalsChloroquineMiceOxindolesPlasmodium falciparumAntimalarialsChloroquineOxindolesTetrahydroisoquinolinesantimalarial drugsin vivo efficacyspiroquindolones

Identifiers

PMID36409128
PMCPMC9765129
OpenAlexW4309516369

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.